GSHD insider grant: CFO/COO awarded 20,000 options, ten-year term
Rhea-AI Filing Summary
Goosehead Insurance reported that Mark E. Jones Jr., the company's CFO and COO and a director, was granted an employee stock option to purchase 20,000 shares of Class A common stock at an exercise price of $95.27. The option becomes exercisable on the grant date and expires ten years later, with vesting structured so one-third of the shares vest on each of the first three anniversaries of the grant date, subject to continued employment. The award includes a provision that accelerates vesting if the holder's employment is terminated without cause or for good reason within six months following a change in control.
Positive
- Alignment with shareholders: Option award ties executive compensation to future stock performance through a market-priced exercise.
- Standard vesting: One-third annual vesting encourages retention over multiple years.
- Change-in-control protection: Acceleration clause offers executive protection in M&A scenarios, which can aid continuity.
Negative
- Missing context on dilution: Filing does not state total outstanding shares or grant as percentage of equity, limiting assessment of investor impact.
- No performance conditions disclosed: Vesting is time-based only, so incentives are not explicitly tied to operational or financial targets.
Insights
TL;DR A 20,000-share option grant to the CFO/COO at $95.27 is routine executive compensation without immediate dilution.
The grant aligns executive incentives with shareholder value by using time-based vesting and a ten-year exercise window. The one-third annual vesting schedule is standard, and the change-in-control acceleration is a common protective feature. The award size and strike price should be assessed relative to total outstanding shares and recent stock price to measure potential dilution and incentive magnitude; that data is not provided in this filing.
TL;DR Vesting and change-in-control acceleration reflect standard governance practices for senior executives.
The documented vesting schedule and post-change-in-control acceleration mirror common market practice to retain executives and protect them in M&A events. The filing discloses the terms clearly but does not include contextual metrics such as percentage of outstanding equity represented by the grant or performance-based conditions, which limits assessment of governance impact.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Options (right to buy) | 20,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. One third (1/3rd) of the shares subject to the option shall vest and become exercisable, subject to continued employment, on each of the first, second, and third anniversaries of the grant date; provided that all shares subject to the option will vest and become exercisable if, within six months following a "change in control" (as defined in the Issuer's Amended and Restated Omnibus Incentive Plan (the "Plan")), the reporting person's employment is terminated without "cause" or for "good reason" (each as defined in the reporting person's option award agreement or the Issuer's Plan).
FAQ
What did GSHD disclose about Mark E. Jones Jr.'s compensation?
How does the vesting schedule for the option work?
Is there any accelerated vesting included in the award?
What is the exercise period for the option?
AI-generated analysis. How Rhea-AI works. Not financial advice.